IM Cannabis Corp. (IMC) is a Multi-Country Operator (MCO) in the medical and adult-use recreational cannabis sector headquartered in Israel with operations In Israel, Germany and Canada. The company is a leader in the Israeli cannabis market, where it was one of the pioneers and founders of the cannabis sector. With its premium flowers and extracts known by physicians and patients in Israel for over a decade, IMC’s brand and strains have become synonymous with quality and consistency. As an MCO, IMC is active in the world’s largest federally legal cannabis market.
In Europe, IMC operates through Adjupharm GmbH (“Adjupharm”), a German-based subsidiary and EU GMP-certified medical cannabis processor and distributor. IMC’s European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.
In Canada, IMC operates through Trichome JWC Acquisition Corp. JWC is a licensed producer located in Kitchener, Ontario, selling cannabis flower, pre-rolls, hash and kief in the Canadian recreational cannabis market under the JWC and Wagners brands. JWC operates with high standards for providing clean, consistent, aeroponically-grown premium cannabis products to medical patients and the adult-use market throughout Canada and the world. At the end of Q1, 2021 IMC entered into a definitive agreement to acquire MYM Nutraceuticals Inc. and its licensed producer subsidiary, Highland Grow Inc. This transaction, if completed, will reinforce IMC’s goal of being a leading global premium cannabis producer and purveyor.
Our Roots – About Focus Medical Herbs Ltd
As one of the global medical cannabis industry pioneers, the IMC brand was launched back in 2010 in Israel, the modern-era bedrock of cannabinoid-based therapies and medical cannabis research.
Focus Medical, one of eight original licensed producers of medical cannabis in Israel, has been cultivating IC branded cannabis for over 10 years, growing high quality medical cannabis in the Israeli market. Focus Medical has an exclusive commercial agreement with IMC to distribute its production under the IMC brand. In addition to its own capacity, Focus Medical has supply agreements with six other cultivators for additional supply using its proprietary genetics and for sale under the IMC brand.
Leveraging long-term extensive experience and insights, IMC has successfully built brand recognition and loyalty among patients and physicians for its premium, consistent, high-quality medical cannabis products.
The company’s unparalleled expertise, proprietary processes and technologies and data-driven insights have enabled it to branch out and expand its business offerings to provide intellectual property related services and consultancy to the medical cannabis industry.
Seeing firsthand the benefits cannabinoid-based therapies bring to patients in alleviating and treating symptoms for various and often severe medical conditions, IMC has set a long-term goal to bring its premium medical cannabis products to more patients around the world through its strategic global expansion plan.
IMC’s primary European center of operations is in Germany, the largest and most advanced legal Cannabis market outside of North America and Israel. The German-based IMC subsidiary, Adjupharm GmbH, is an EU-GMP certified medical cannabis and pharmaceutical distributor which acts as the Company’s European hub and a gateway for future continent expansion. With an on-the-ground presence in the German market, the Company’s branded medical cannabis products are already being distributed to pharmacies, prescribed by physicians, and used by patients across Germany, further establishing IMC as a global brand.
IMC’s European presence is also augmented through strategic alliances with EU-GMP certified suppliers and distributors across the continent. This network provides IMC with the additional breadth, depth and scalability required to expand in Germany and throughout Europe as more jurisdictions move toward cannabis market reforms.
As IMC’s third geographical pillar, the company has extended its Canadian market footing through the acquisition of Canadian-based Trichome Financial Corp. As a publicly listed company on the Canadian Securities Exchange (CSE: IMCC), this acquisition enhances IMC’s operational presence in Canada across various dimensions. It provides the Company with an advanced indoor cultivation and processing facility that diversifies IMC’s supply sources to local and international markets and adds an interprovincial distribution network for selling the Company’s products in the legal adult-use recreational and medical cannabis segments.
Furthermore, the acquisition of Trichome enhances IMC leadership’s bench strength thanks to the addition of a seasoned Canadian management team with M&A and restructuring expertise to further drive the Company’s growth in one of the world’s top three legal cannabis markets.
The team’s furst acquisition is MYM Nutraceuticals Inc. and its licensed producer subsidiary, Highland Grow Inc., a deal which is expected to close in the 2nd half of 2021.
IMC plans to bring its premium products to medical patients and adult-use consumers around the world through continued expansion of its global presence. The company will accomplish this goal through a measured and purposeful acquisition strategy that hinges on:
- The company’s unparalleled experience and data driven insights
- A lean and proactive approach aimed at driving profitability
- Focusing on attractively valued and highly synergetic acquisition targets
This formulation will continue to propel IMC as a driving force in the international medical cannabis industry.